Immunologic Deficiency Syndromes Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Immunologic Deficiency Syndromes. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Immunologic Deficiency Syndromes receives a directional score of 58/100, combining unmet need (59/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.

The reproducible record is Patsnap disease ID 2bc69f76880b4ff1836b7813c052edb8 and MeSH identifier D007153. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: The epidemiology and clinical feature of selective immunoglobulin a deficiency of Zhejiang Province in China

SIgAD is the most prevalent primary immunodeficiency, found at the highest frequency of 1 in 142 in Caucasians and a low of 1 in 18,550 among Japanese, with a prevalence among other ethnici- ties ranging between these values.13 In China, Feng 11 investigated 22 609 healthy blood donors from single blood center on the criteria of IgA < 0.05 g/L, and 14 SIgAD individuals were found, and the prevalence is 0.062% in Shanghai blood donors in 2011. Another 7989 Peking suburb residents in 1987 showed that the incidence of SIgAD was 0.037%, and the epidemiological study of SIgAD in- dividuals among 6 nationalities in China showed that the incidence of SIgAD was 0.024% in 1992. However, children below 4 years old were also included in these two studies in 1987 and 1992. In this study, the incidence of hospital patients (including outpatient and in- patient) and physical examination is 0.021% and 0.006% separately, lower than three previous Chinese reports in healthy blood donors and hospital patients. Furthermore, when compare to the hospital patients 0.033% in Japan, 0.021% for hospital patients in this study were lower than Japan.4 Similarly, the 0.006% in physical examina- tion in this study was similar for the 0.004% and 0.005% incidence for the blood donors in Japan. However, all these SIgAD subjects were defined as IgA level < 0.05 g/L. Therefore, the incidences can- not be compared on the different diagnosis criteria.4 These different incidences may due to the changing diagnostic criteria for SIgAD or different genetic backgrounds.13

Review source

Epidemiology evidence 2: Incidence and prevalence of autoimmune diseases in China: A systematic review and meta-analysis of epidemiological studies

Due to the difference in the magnitude of estimates between condi­ tions, we grouped conditions into “low prevalence” (CD, UC, IBD, MS, T1D and SLE) and “high prevalence” (RA, GD and AT) groups, based on whether the pooled estimates were lower than 100 per 100,000 persons, or greater, respectively. For CD and UC, the fixed-effects pooled esti­ mates were 3.73 (95% CI 3.68–3.78), 16.11 (15.93–16.29) and random- effects estimates were 3.40 (0.50–22.92) and 12.59 (4.46–35.55) per 100,000 persons, respectively, based on four studies covering Taiwan, Hong Kong and mainland China (Fig. 3) [26,27,37,38]. Several other studies were identified but were excluded due to partial overlap or insufficient data (Supplementary Table 3). The Hong Kong studies, [27] which used active case finding had higher prevalence than the Taiwan[26,39] and mainland China studies, [37,38] which did not. For MS (7 estimates; 7 studies) the pooled estimates were 4.08 (3.95–4.21) and 2.45 (1.40–4.29) per 100,000 persons in the fixed-effects and random-effects models, respectively [33,40–45]. One prevalence esti­ mate was identified for T1D of 47.90 (95% CI 47.01–48.79) per 100,000 persons in Taiwan [46]. For SLE (6 estimates; 6 studies) the pooled es­ timates were 93.44 (92.27–94.63) and 60.30 (41.28–88.08) per 100,000 persons in the fixed-effects and random-effects models, respectively [47–52]. Except for SLE, where two of the studies were based on survey data, all other estimates in the “low prevalence” group were based on Fig. 2. Incidence of autoimmune diseases.

Review source

Epidemiology evidence 3: Sex Differences in Autoimmune Multimorbidity Across Eleven Disorders: A Real-World Primary Care Study in Germany Sex Differences in Autoimmune Multimorbidity Across ElevenDisorders: A Real-World Primary Care Study in Germany

1. Pisetsky, D.S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 2023, 19, 509–524. [CrossRef] 2. Miller, F.W. The increasing prevalence of autoimmunity and autoimmune diseases: An urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr. Opin. Immunol. 2023, 80, 102266. [CrossRef] [PubMed] 3. Conrad, N.; Misra, S.; Verbakel, J.Y.; Verbeke, G.; Molenberghs, G.; Taylor, P.N.; Mason, J.; Sattar, N.; McMurray, J.J.V.; McInnes, I.B.; et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. Lancet 2023, 401, 1878–1890. [CrossRef] 4. Angum, F.; Khan, T.; Kaler, J.; Siddiqui, L.; Hussain, A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. Cureus 2020, 12, e8094. [CrossRef] [PubMed] 5. Yalcinkaya, A.; Yalcinkaya, R.; Sardh, F.; Landegren, N. Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy. Front. Immunol. 2025, 15, 1501364. [CrossRef] [PubMed] 6. Sciarra, F.; Campolo, F.; Franceschini, E.; Carlomagno, F.; Venneri, M.A. Gender-Specific Impact of Sex Hormones on the Immune System. Int. J. Mol. Sci. 2023, 24, 6302. [CrossRef] 7. Tripathi, P.; Bhushan, D.; Banerjee, A.; Mahto, M. The Kaleidoscope of Polyautoimmunity: An Odyssey of Diagnostic Dilemmas. Cureus 2024, 16, e57799. [CrossRef] 8. Sohn, S.Y.; Ahn, J.; Lee, M.K.; Lee, J.H.; Kwon, J.W.; Kweon, J.M.; Lee, J.Y. Risk of non-thyroidal autoimmune diseases in pati

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Immunologic Deficiency Syndromes, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Immunologic Deficiency Syndromes thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor is IL1B, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 12719 registered studies.

• NCT07785388 — Genistein for the Reduction of Adverse Cardiovascular Events (GRACE) (GRACE); Not yet recruiting; Phase 1/2; sponsor Greenstone Biosciences, Inc.; enrollment 60.
• ChiCTR2600130797 — Effect of Hepatitis B Surface Antibody Titer Testing on Uptake of Quadruple Infectious Disease Testing Among Primary Care Attendees: A Cluster Randomized Controlled Trial; Not yet recruiting; Not Applicable; sponsor Guangxi Medical University; enrollment 1080.
• NCT07781423 — Nurse-Led PrEP Initiation Among Incarcerated Individuals (SWIFT); Not yet recruiting; Not Applicable; sponsor Rhode Island Hospital; enrollment 90.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 9 directly matched 2023–2026 transactions.

• 申联生物旗下全资子公司上海本天成生物医药有限公司将斥资6000万元，取得创新药企业扬州世之源生物科技有限责任公司20.48%的股权 (2025-02-06). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada (2024-12-04). Review stage, rights, territory, milestones and economics before using it as a comparable.
• Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries (2024-10-03). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate IL1B relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Immunologic Deficiency Syndromes merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Immunologic Deficiency Syndromes is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.